about
Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenationThe development of immunoconjugates for targeted cancer therapySpectroscopic and computational investigation of actinium coordination chemistryImpact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapyRadioimmunotherapy with α-particle-emitting radionuclides.Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapyApplication of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.Molecular pathways: targeted α-particle radiation therapy.Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb.Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.Methodology for labeling proteins and peptides with lead-212 (212Pb)Encapsulation of α-Particle-Emitting 225Ac3+ Ions Within Carbon Nanotubes.Radio-nanomaterials for biomedical applications: state of the artTargeted α-particle therapy of bone metastases in prostate cancerSublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.Synthesis and Characterization of the Actinium Aquo Ion.Bismuth compounds in medicinal chemistry.Radioimmunotherapy for peritoneal cancers.A nuclear chocolate box: the periodic table of nuclear medicine.Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns.Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy.A review of solute encapsulating nanoparticles used as delivery systems with emphasis on branched amphipathic peptide capsules.Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns.Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts.Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma.Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer TreatmentBranched amphiphilic peptide capsules: cellular uptake and retention of encapsulated solutes.Development of separation technology for the removal of radium-223 from decayed thorium-227 in drug formulations. Material screening and method development.Ra-224 Labeling of Calcium Carbonate Microparticles for Internal α-Therapy: Preparation, Stability and Biodistribution in Mice.An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.The coordination chemistry of Cm, Am, and Ac in nitrate solutions: an actinide L-edge EXAFS study
P2860
Q21133512-C717665F-8832-4DED-B23A-0AD73F71023CQ27021990-FE5CF0CC-0F69-4E91-87F8-E25D76AFEFBDQ28829564-180E4519-0C2B-45CC-A594-6D83716899FAQ34277296-E5489ED5-8AD9-4B69-83CF-CDB52E2B2098Q34324413-8F842F50-19A2-4570-A90A-EA56B26F6FBCQ34419562-6478CF09-69D1-42CE-804A-6074F0B2CE77Q36088727-17705A55-DDFC-48C0-90FD-7F2B80594CE7Q36534262-6989DE92-5B9C-41F8-9809-EC3A5567D3F1Q36551498-1C356D11-13B8-4DCF-9DB2-6824BFE9A65AQ36585767-5E631B7A-D700-446B-90E7-FC6B95A41C23Q36752488-8D724880-5571-4DCF-8C66-6CE8F59F7861Q36838996-AC701DF1-BDCF-4E7C-B3B1-7A1B2E17F007Q36881360-B7E22021-BD32-44B3-B269-4C2235772B0EQ36890774-93FD5BBC-9729-4E84-B5B9-C17490CC9EF7Q37131224-868EF226-BAE5-4CF7-B895-D8611396CDAFQ37417656-BE982800-14D6-4B71-9803-9634D11FDCA7Q37686296-C954C811-75C2-4AC3-9095-20BB8982403AQ37719375-AEF921EC-D094-4C70-B520-C69C8309156EQ38031636-B58AC512-9EFA-4F54-938D-12453437058DQ38096059-58743EA8-AEBC-48C2-B0DA-241E146AC695Q38269216-511502F0-33BC-4EFB-87DF-55518155CBF3Q38663041-75FE4960-157C-4250-8687-477B94635E19Q38731409-372EE75F-FE96-4EEA-933F-7F3BB253D6CCQ38733823-FBAFBC87-8220-4F49-871A-C97AD66452F7Q38754657-626F2D11-7A42-4F2F-8856-8EEED8298F56Q38821299-43051087-B321-4337-9C0D-301C4E401EB6Q41027410-DD3FF87F-1BC4-427B-AA63-5A8D41B4890EQ41346916-7B4A2498-5806-43BA-A91A-13223A547E5BQ41475179-A31DC2DC-8D50-4B1C-A73A-6C3BEF471D27Q42174106-E5103145-4DE1-4C47-83DE-B01C2592D9C3Q46639253-907533D5-029C-4B7D-ABAB-0D20374D30BBQ48144362-9EBB163C-6503-40F8-865F-E8FEB55CB83EQ48265569-67BF2EEF-2F7C-4EFC-B4B5-D98DBE567C0FQ50149863-1170F052-58AC-43D0-8BE0-6B1D49C5C11CQ57495777-DA1CB211-2F2E-452B-A25D-2B8898A9B11A
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An overview of targeted alpha therapy.
@ast
An overview of targeted alpha therapy.
@en
An overview of targeted alpha therapy.
@nl
type
label
An overview of targeted alpha therapy.
@ast
An overview of targeted alpha therapy.
@en
An overview of targeted alpha therapy.
@nl
prefLabel
An overview of targeted alpha therapy.
@ast
An overview of targeted alpha therapy.
@en
An overview of targeted alpha therapy.
@nl
P2860
P1433
P1476
An overview of targeted alpha therapy.
@en
P2093
Martin W Brechbiel
Young-Seung Kim
P2860
P2888
P304
P356
10.1007/S13277-011-0286-Y
P577
2011-12-06T00:00:00Z
P6179
1001308897